Product-Related

Publications

1. Camptothecin resistance is determined by regulation of topoisomerase I degradation mediated by ubiquitin proteasomal pathway. Ando, K, Shah, AK, Sachdev V, Kleinstiver BP, Welch MM, Taylor-Parker J, Hu Y, Salgia R, White FM, Parvin JD, Ozonoff A, Rameh LE, Joung JK and Bharti A. Oncotarget 2017 Jul 4; 8(27): 43733-43751.  

2. Developing a phosphospecific Immunohistochemistry Assay as a Predictive Biomarker for Topoisomerase I Inhibitors Ando K, Tohme Y, Srinivasiah A, Taylor-Parker J , Harrington Y, Shah AK, Oki E, Brahmandam M and Bharti A. . J. Histochemistry and Cytochemistry. 2018 66(8): 549-561

3.  CTDSP1 inhibitor rabeprazole regulates DNA-PKcs dependent topoisomerase I degradation and irinotecan drug resistance in colorectal cancer.

Matsuoka H , Ando K, Swayze EJ , Unan EC , Mathew J, Hu Q , Tsuda Y , Yuichiro N,  Saeki  H, Oki E, Bharti A,  Mori M. . PLoS One 2020 Aug 7;15(8):e0228002.doi: 10.1371/journal.pone.0228002. eCollection 2020

4. Multi-Cohort Retrospective Validation of a Predictive Biomarker for Topoisomerase I Inhibitors. Ando K, Ozonoff A, Lee S, Voisine M, Parker J, Nakanishi R, Nishimura S, Yang J, Grace Z, Tran B, Diefenbach T, Maehara Y, Yasui H, Irino T, Salgia R, Terashima M, Gibbs P, Ramanathan R, Oki E, Mori M, Kulke M, Hartshorn K, and Bharti A. Clinical Colorectal Cancer. 2021 June 21:2 129-38.

5. Rapid rate of Ubiquitination and proteasomal degradation of topoI protein ensures anticancer drug resistance. Unan E, Bharti A et al (In Press)

6. The efficacy of topoI-pS10 expression in gastric cancer as predictive biomarker for irinotecan use. Ando K, Hu Q, Fujimoto Y, Jogo T, Nakanishi R, Hisamatsu Y, Kimura Y, Oki E, Bharti A, Mori M.  Gan To Kagaku Ryoho. 2021 Mar; 48(3):331-335.